Top news of the week: 28.07.2020.

#COVID19 #news #pharma #pharmiweb #synbio #biotech #pharmaceuticals #CoronaOutbreak #Coronavirus #biotechnology

Career And Jobs

On Jul 24, 2020
@BiotechWorld shared
Parker Institute names Connolly as CSO, targets biopharma pacts https://t.co/cDHnyqa4Oi https://t.co/CKjkVrkLH2
Open

Parker Institute names Connolly as CSO, targets biopharma pacts

Parker Institute names Connolly as CSO, targets biopharma pacts

The Parker Institute for Cancer Immunotherapy has named John Connolly, Ph.D., as its chief scientific officer. Connolly joins PICI having previously collaborated with the institute in his ...

On Jul 22, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: July 22 https://t.co/Yq5G7zAxeU #biospace #lifesciences #biotechnology #pharmaceuticals #Coronavirus #COVID19 #CoronaOutbreak #CoronaPandemic
Open

Biopharma Update on the Novel Coronavirus: July 22

Biopharma Update on the Novel Coronavirus: July 22

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.

On Jul 23, 2020
@pharminews shared
Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology https://t.co/js2JhoxOGH #news #pharma #pharmiweb
Open

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation ...

On Jul 27, 2020
@SynBioBeta shared
This panel will highlight several successful paths that scientists can take toward creating a successful #biotech company. https://t.co/rfn0UXlYGo @indbio #synbio
Open

Turning a good scientific idea into a successful biotech startup is a challenging journey.

Turning a good scientific idea into a successful biotech startup is a challenging journey.

Learn about NY-based programs supporting biotech startups in this panel featuring the Center for Biotechnology, IndieBio, and BARDA-DRIVe.

On Jul 22, 2020
@pharminews shared
British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies https://t.co/o8YobtOIFY #news #pharma #pharmiweb
Open

British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies

British Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies

SV Health Investors closes first fund dedicated to biotechnology at $265mInvestment builds on British Patient Capital’s current commitments to life sciences 20th July 2020 ...

On Jul 24, 2020
@SynBioBeta shared
[email protected] Announces Publication of Clinical Data On New Method for Detecting #COVID19 Neutralizing Antibodies In Nature Biotechnology https://t.co/thTQRdlkiy
Open

GenScript Announces Publication of Clinical Data On New Method for Detecting COVID-19 Neutralizing Antibodies In Nature Biotechnology

GenScript Announces Publication of Clinical Data On New Method for Detecting COVID-19 Neutralizing Antibodies In Nature Biotechnology

GenScript announced that clinical data on a new method for detecting COVID-19 neutralizing antibodies in serum indicates it is safer, faster, easier and more effective than traditional ...

On Jul 24, 2020
@JohnCendpts shared
Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK $CVAC $GSK $LLY $TSLA https://t.co/zQltPua0m5
Open

Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK

Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK

One of the most secretive biotech candidates to lead the development of a new mRNA vaccine to fight Covid-19 just filed their IPO papers for Nasdaq. CureVac, which has been slow to reveal ...

On Jul 23, 2020
@SynBioBeta shared
This #Biotech Business Won't Let Cost Get in the Way of a #Covid Cure: Synthetic gene manufacturer @ATUM_bio turned down #venturecapital. That's why it's free to do whatever it takes to fight #Covid19. https://t.co/l4RxuW62vf @LeighEBuchanan #synbio
Open

This Biotech Business Won't Let Cost Get in the Way of a Covid Cure

This Biotech Business Won't Let Cost Get in the Way of a Covid Cure

Synthetic gene manufacturer ATUM turned down venture capital. That's why it's free to do whatever it takes to fight Covid-19.